Schneider, Günter

[["dc.bibliographiccitation.firstpage","1301"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Flebbe, Hannah; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Spitzner, Melanie; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Marquet, Philipp Enno; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Gaedcke, Jochen; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Ghadimi, B. Michael; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Rieken, Stefan; 3Department of Radiotherapy and Radiooncology, University Medical Center Goettingen, 37075 Goettingen, Germany; stefan.rieken@med.uni-goettingen.de"],["dc.contributor.affiliation","Schneider, Günter; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Koenig, Alexander O.; 4Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, 37075 Goettingen, Germany; alexander.koenig@med.uni-goettingen.de"],["dc.contributor.affiliation","Grade, Marian; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; hannah.flebbe@med.uni-goettingen.de (H.F.); melanie.spitzner@med.uni-goettingen.de (M.S.); pmarquet@tabea-krankenhaus.de (P.E.M.); jochen.gaedcke@med.uni-goettingen.de (J.G.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.author","Flebbe, Hannah"],["dc.contributor.author","Spitzner, Melanie"],["dc.contributor.author","Marquet, Philipp Enno"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Schneider, Günter"],["dc.contributor.author","Koenig, Alexander O."],["dc.contributor.author","Grade, Marian"],["dc.date.accessioned","2022-04-01T10:00:34Z"],["dc.date.available","2022-04-01T10:00:34Z"],["dc.date.issued","2022"],["dc.date.updated","2022-04-08T08:31:13Z"],["dc.description.abstract","The debate is ongoing regarding the potential role of preoperative chemoradiotherapy (CRT) for patients with pancreatic ductal adenocarcinoma (PDAC), and whether it should be reserved for borderline resectable or unresectable tumors. However, treatment response is heterogeneous, implicating the need to unveil and overcome the underlying mechanisms of resistance. Activation of the transcription factor STAT3 was recently linked to CRT resistance in other gastrointestinal cancers such as rectal and esophageal cancers, but its role in PDAC needs to be clarified. Protein expression and phosphorylation of STAT3 was determined in PDAC cell lines and connected to transcriptional activity measured by dual-luciferase reporter gene assays. Inhibition of STAT3 signaling was achieved by RNAi or the small-molecule inhibitor napabucasin. We observed a positive correlation between STAT3 signaling activity and CRT resistance. Importantly, genetical and pharmacological perturbation of the IL-6/STAT3 pathway resulted in CRT sensitization specifically in those cell lines, in which STAT3 activity was augmented by IL-6. In conclusion, our data underscore the general importance of IL-6/STAT3 signaling for CRT resistance and suggest that pathway inhibition may represents a putative treatment strategy in order to increase the fraction of patients with PDAC who are candidates for surgical approaches."],["dc.identifier.doi","10.3390/cancers14051301"],["dc.identifier.pii","cancers14051301"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105459"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","2072-6694"],["dc.rights","Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)."],["dc.title","Targeting STAT3 Signaling Facilitates Responsiveness of Pancreatic Cancer Cells to Chemoradiotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","10301"],["dc.bibliographiccitation.issue","19"],["dc.bibliographiccitation.journal","International Journal of Molecular Sciences"],["dc.bibliographiccitation.volume","22"],["dc.contributor.affiliation","Spitzner, Melanie; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; melanie.spitzner@med.uni-goettingen.de (M.S.); georg.emons@med.uni-goettingen.de (G.E.); karlburkhard.schuetz@sanktgeorg.de (K.B.S.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Emons, Georg; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; melanie.spitzner@med.uni-goettingen.de (M.S.); georg.emons@med.uni-goettingen.de (G.E.); karlburkhard.schuetz@sanktgeorg.de (K.B.S.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Schütz, Karl Burkhard; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; melanie.spitzner@med.uni-goettingen.de (M.S.); georg.emons@med.uni-goettingen.de (G.E.); karlburkhard.schuetz@sanktgeorg.de (K.B.S.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Wolff, Hendrik A.; 3Department of Radiotherapy and Radiooncology, University Medical Center Goettingen, 37075 Goettingen, Germany; h.wolff@strahlentherapie-muenchen.eu (H.A.W.); stefan.rieken@med.uni-goettingen.de (S.R.)"],["dc.contributor.affiliation","Rieken, Stefan; 3Department of Radiotherapy and Radiooncology, University Medical Center Goettingen, 37075 Goettingen, Germany; h.wolff@strahlentherapie-muenchen.eu (H.A.W.); stefan.rieken@med.uni-goettingen.de (S.R.)"],["dc.contributor.affiliation","Ghadimi, B. Michael; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; melanie.spitzner@med.uni-goettingen.de (M.S.); georg.emons@med.uni-goettingen.de (G.E.); karlburkhard.schuetz@sanktgeorg.de (K.B.S.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Schneider, Günter; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; melanie.spitzner@med.uni-goettingen.de (M.S.); georg.emons@med.uni-goettingen.de (G.E.); karlburkhard.schuetz@sanktgeorg.de (K.B.S.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.affiliation","Grade, Marian; 1Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, 37075 Goettingen, Germany; melanie.spitzner@med.uni-goettingen.de (M.S.); georg.emons@med.uni-goettingen.de (G.E.); karlburkhard.schuetz@sanktgeorg.de (K.B.S.); mghadim@uni-goettingen.de (B.M.G.); guenter.schneider@med.uni-goettingen.de (G.S.)"],["dc.contributor.author","Spitzner, Melanie"],["dc.contributor.author","Emons, Georg"],["dc.contributor.author","Schütz, Karl Burkhard"],["dc.contributor.author","Wolff, Hendrik A."],["dc.contributor.author","Rieken, Stefan"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Schneider, Günter"],["dc.contributor.author","Grade, Marian"],["dc.date.accessioned","2021-12-01T09:23:14Z"],["dc.date.available","2021-12-01T09:23:14Z"],["dc.date.issued","2021"],["dc.date.updated","2022-09-03T10:10:11Z"],["dc.description.abstract","The standard treatment of locally advanced esophageal cancer comprises multimodal treatment concepts including preoperative chemoradiotherapy (CRT) followed by radical surgical resection. However, despite intensified treatment approaches, 5-year survival rates are still low. Therefore, new strategies are required to overcome treatment resistance, and to improve patients’ outcome. In this study, we investigated the impact of Wnt/β-catenin signaling on CRT resistance in esophageal cancer cells. Experiments were conducted in adenocarcinoma and squamous cell carcinoma cell lines with varying expression levels of Wnt proteins and Wnt/β-catenin signaling activities. To investigate the effect of Wnt/β-catenin signaling on CRT responsiveness, we genetically or pharmacologically inhibited Wnt/β-catenin signaling. Our experiments revealed that inhibition of Wnt/β-catenin signaling sensitizes cell lines with robust pathway activity to CRT. In conclusion, Wnt/β-catenin activity may guide precision therapies in esophageal carcinoma patients."],["dc.description.abstract","The standard treatment of locally advanced esophageal cancer comprises multimodal treatment concepts including preoperative chemoradiotherapy (CRT) followed by radical surgical resection. However, despite intensified treatment approaches, 5-year survival rates are still low. Therefore, new strategies are required to overcome treatment resistance, and to improve patients’ outcome. In this study, we investigated the impact of Wnt/β-catenin signaling on CRT resistance in esophageal cancer cells. Experiments were conducted in adenocarcinoma and squamous cell carcinoma cell lines with varying expression levels of Wnt proteins and Wnt/β-catenin signaling activities. To investigate the effect of Wnt/β-catenin signaling on CRT responsiveness, we genetically or pharmacologically inhibited Wnt/β-catenin signaling. Our experiments revealed that inhibition of Wnt/β-catenin signaling sensitizes cell lines with robust pathway activity to CRT. In conclusion, Wnt/β-catenin activity may guide precision therapies in esophageal carcinoma patients."],["dc.identifier.doi","10.3390/ijms221910301"],["dc.identifier.pii","ijms221910301"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94598"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.eissn","1422-0067"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Inhibition of Wnt/β-Catenin Signaling Sensitizes Esophageal Cancer Cells to Chemoradiotherapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]